Introduction: Coronavirus disease 2019 (COVID-19) is a novel viral disease that spread as a global pandemic in 2020 by infecting millions of people across the world. Its clinical prognosis is dependent on various coagulatory parameters since thrombotic events are frequently associated with infection severity. Methods: A total of 383 COVID-19 patients enrolled in Rajiv Gandhi Super Specialty Hospital, Delhi, India, were included in the present retrospective study. Patients were divided into three categories, severe (n = 141), moderate (n = 138), and mild (n = 104) based on infection severity. Various thrombotic parameters and anticoagulant levels were measured in 70 patients and further analyzed. Results: Coagulopathy is seen in COVID-19 patients (n = 70) with a significant increase in fibrinogen, D-dimer levels, and prothrombin time in patients with severe and moderate disease compared to patients with a mild infection. Approximately, 70% of patients with severe and moderate disease demonstrated fibrinogen levels higher than the standard reference range. 60.41% of patients with severe disease showed significantly higher D-dimer levels. Thrombotic parameters were notably elevated in the nonsurvivors group compared to COVID-19 survivors. Nearly, 91% of patients with severe infection had anticoagulant protein S levels below the reference range. Conclusion: COVID-19 infection severely impacts the blood coagulation cascade, which might lead to the manifestation of severe symptoms and increased mortality in patients.

1.
Huang
C
,
Wang
Y
,
Li
X
,
Ren
L
,
Zhao
J
,
Hu
Y
,
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
.
Lancet
.
2020 Feb 15
;
395
(
10223
):
497
506
.
2.
World Health Organization
.
Coronavirus disease (COVID-19) situation reports
.
World Health Organization
;
2020
. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/ (accessed July 13, 2020.
3.
Ikewaki
N
,
Rao
KS
,
Archibold
AD
,
Iwasaki
M
,
Senthilkumar
R
,
Preethy
S
,
Coagulopathy associated with COVID-19: perspectives & preventive strategies using a biological response modifier glucan
.
Thromb J
.
2020 Dec
;
18
(
1
):
27
.
4.
Getu
S
,
Tiruneh
T
,
Andualem
H
,
Hailemichael
W
,
Kiros
T
,
Mesfin Belay
D
,
Coagulopathy in SARS-CoV-2 infected patients: implication for the management of COVID-19
.
J Blood Med
.
2021
;
12
:
635
43
.
5.
Brosnahan
SB
,
Jonkman
AH
,
Kugler
MC
,
Munger
JS
,
Kaufman
DA
.
COVID-19 and respiratory system disorders: current knowledge, future clinical and translational research questions
.
Arterioscler Thromb Vasc Biol
.
2020 Nov
;
40
(
11
):
2586
97
. .
6.
Tang
N
,
Li
D
,
Wang
X
,
Sun
Z
.
Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia
.
J Thromb Haemost
.
2020
;
18
(
4
):
844
7
. .
7.
Klok
FA
,
Kruip
MJ
,
Van der Meer
NJ
,
Arbous
MS
,
Gommers
DA
,
Kant
KM
,
Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis
.
Thromb Res
.
2020 Jul 1
;
191
:
148
50
.
8.
Helms
J
,
Tacquard
C
,
Severac
F
,
Leonard-Lorant
I
,
Ohana
M
,
Delabranche
X
,
High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study
.
Intensive Care Med
.
2020 Jun
;
46
(
6
):
1089
98
.
9.
Llitjos
JF
,
Leclerc
M
,
Chochois
C
,
Monsallier
JM
,
Ramakers
M
,
Auvray
M
,
High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients
.
J Thromb Haemost
.
2020 Jul
;
18
(
7
):
1743
6
.
10.
Zhang
L
,
Feng
X
,
Zhang
D
,
Jiang
C
,
Mei
H
,
Wang
J
,
Deep vein thrombosis in hospitalized patients with COVID-19 in Wuhan, China: prevalence, risk factors, and outcome
.
Circulation
.
2020 Jul 14
;
142
(
2
):
114
28
.
11.
Léonard-Lorant
I
,
Delabranche
X
,
Séverac
F
,
Helms
J
,
Pauzet
C
,
Collange
O
,
Acute pulmonary embolism in patients with COVID-19 at CT angiography and relationship to D-dimer levels
.
Radiology
.
2020 Sep
;
296
(
3
):
E189
91
.
12.
Middeldorp
S
,
Coppens
M
,
van Haaps
TF
,
Foppen
M
,
Vlaar
AP
,
Müller
MC
,
Incidence of venous thromboembolism in hospitalized patients with COVID-19
.
J Thromb Haemost
.
2020 Aug
;
18
(
8
):
1995
2002
.
13.
Bompard
F
,
Monnier
H
,
Saab
I
,
Tordjman
M
,
Abdoul
H
,
Fournier
L
,
Pulmonary embolism in patients with COVID-19 pneumonia
.
Eur Respir J
.
2020 Jul 1
;
56
(
1
):
2001365
.
14.
Poissy
J
,
Goutay
J
,
Caplan
M
,
Parmentier
E
,
Duburcq
T
,
Lassalle
F
,
Pulmonary embolism in patients with COVID-19: awareness of an increased prevalence
.
Circulation
.
2020 Jul 14
;
142
(
2
):
184
6
.
15.
Ahmed
S
,
Zimba
O
,
Gasparyan
AY
.
Thrombosis in Coronavirus disease 2019 (COVID-19) through the prism of Virchow’s triad
.
Clin Rheumatol
.
2020 Jul 11
;
39
(
9
):
2529
43
.
16.
Hamming
I
,
Timens
W
,
Bulthuis
ML
,
Lely
AT
,
Navis
G
,
van Goor
H
.
Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis
.
J Pathol
.
2004 Jun
;
203
(
2
):
631
7
. .
17.
Zhu
N
,
Zhang
D
,
Wang
W
,
Li
X
,
Yang
B
,
Song
J
,
A novel coronavirus from patients with pneumonia in China, 2019
.
N Engl J Med
.
2020 Feb 20
;
382
(
8
):
727
33
.
18.
Escher
R
,
Breakey
N
,
Lämmle
B
.
Severe COVID-19 infection associated with endothelial activation
.
Thromb Res
.
2020 Jun 1
;
190
:
62
. .
19.
Philippe
A
,
Chocron
R
,
Gendron
N
,
Bory
O
,
Beauvais
A
,
Peron
N
,
Circulating Von Willebrand factor and high molecular weight multimers as markers of endothelial injury predict COVID-19 in-hospital mortality
.
Angiogenesis
.
2021 Aug
;
24
(
3
):
505
17
.
20.
Suzuki
Y
,
Yasui
H
,
Brzoska
T
,
Mogami
H
,
Urano
T
.
Surface-retained tPA is essential for effective fibrinolysis on vascular endothelial cells
.
Blood
.
2011 Sep 15
;
118
(
11
):
3182
5
. .
21.
Maier
CL
,
Truong
AD
,
Auld
SC
,
Polly
DM
,
Tanksley
CL
,
Duncan
A
.
COVID-19-associated hyperviscosity: a link between inflammation and thrombophilia?
Lancet
.
2020 Jun 6
;
395
(
10239
):
1758
9
. .
22.
McGonagle
D
,
Sharif
K
,
O’Regan
A
,
Bridgewood
C
.
The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease
.
Autoimmun Rev
.
2020 Jun 1
;
19
(
6
):
102537
. .
23.
Garg
I
,
Srivastava
S
,
Dogra
V
,
Bargotya
M
,
Bhattar
S
,
Gupta
U
,
Potential association of COVID-19 and ABO blood group: an Indian study
.
Microb Pathog
.
2021 Sep
;
158
:
105008
.
24.
Golebiewska
EM
,
Poole
AW
.
Platelet secretion: from haemostasis to wound healing and beyond
.
Blood Rev
.
2015 May 1
;
29
(
3
):
153
62
. .
25.
Rampotas
A
,
Pavord
S
.
Platelet aggregates, a marker of severe COVID-19 disease
.
J Clin Pathol
.
2021 Nov 1
;
74
(
11
):
750
1
. .
26.
Hottz
ED
,
Azevedo-Quintanilha
IG
,
Palhinha
L
,
Teixeira
L
,
Barreto
EA
,
Pão
CR
,
Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19
.
Blood
.
2020 Sep 10
;
136
(
11
):
1330
41
.
27.
Zhang
S
,
Liu
Y
,
Wang
X
,
Yang
L
,
Li
H
,
Wang
Y
,
SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19
.
J Hematol Oncol
.
2020 Dec
;
13
(
1
):
120
.
28.
Lippi
G
,
Plebani
M
,
Henry
BM
.
Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis
.
Clin Chim Acta
.
2020 Jul 1
;
506
:
145
8
. .
29.
Bao
C
,
Tao
X
,
Cui
W
,
Yi
B
,
Pan
T
,
Young
KH
,
SARS-CoV-2 induced thrombocytopenia as an important biomarker significantly correlated with abnormal coagulation function, increased intravascular blood clot risk and mortality in COVID-19 patients
.
Exp Hematol Oncol
.
2020 Dec
;
9
(
1
):
1
8
.
30.
Zong
X
,
Gu
Y
,
Yu
H
,
Li
Z
,
Wang
Y
.
Thrombocytopenia is associated with COVID-19 severity and outcome: an updated meta-analysis of 5637 patients with multiple outcomes
.
Lab Med
.
2021 Jan
;
52
(
1
):
10
5
. .
31.
Gale
AJ
.
Continuing education course# 2: current understanding of hemostasis
.
Toxicologic Pathol
.
2011 Jan
;
39
(
1
):
273
80
.
32.
Bi
X
,
Su
Z
,
Yan
H
,
Du
J
,
Wang
J
,
Chen
L
,
Prediction of severe illness due to COVID-19 based on an analysis of initial fibrinogen to albumin ratio and platelet count
.
Platelets
.
2020 Jul 3
;
31
(
5
):
674
9
.
33.
Han
H
,
Yang
L
,
Liu
R
,
Liu
F
,
Wu
KL
,
Li
J
,
Prominent changes in blood coagulation of patients with SARS-CoV-2 infection
.
Clin Chem Lab Med
.
2020 Jul 1
;
58
(
7
):
1116
20
.
34.
Whyte
CS
,
Morrow
GB
,
Mitchell
JL
,
Chowdary
P
,
Mutch
NJ
.
Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19
.
J Thromb Haemost
.
2020 Jul
;
18
(
7
):
1548
55
. .
35.
Wright
FL
,
Vogler
TO
,
Moore
EE
,
Moore
HB
,
Wohlauer
MV
,
Urban
S
,
Fibrinolysis shutdown correlation with thromboembolic events in severe COVID-19 infection
.
J Am Coll Surg
.
2020 Aug 1
;
231
(
2
):
193
203.e1
.
36.
Tang
N
,
Bai
H
,
Chen
X
,
Gong
J
,
Li
D
,
Sun
Z
.
Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy
.
J Thromb Haemost
.
2020 May
;
18
(
5
):
1094
9
. .
37.
Cummings
MJ
,
Baldwin
MR
,
Abrams
D
,
Jacobson
SD
,
Meyer
BJ
,
Balough
EM
,
Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York city: a prospective cohort study
.
Lancet
.
2020 Jun 6
;
395
(
10239
):
1763
70
.
38.
Long
H
,
Nie
L
,
Xiang
X
,
Li
H
,
Zhang
X
,
Fu
X
,
D-dimer and prothrombin time are the significant indicators of severe COVID-19 and poor prognosis
.
Biomed Res Int
.
2020 Oct
;
2020
:
6159720
.
39.
Massberg
S
,
Grahl
L
,
von Bruehl
ML
,
Manukyan
D
,
Pfeiler
S
,
Goosmann
C
,
Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases
.
Nat Med
.
2010 Aug
;
16
(
8
):
887
96
.
40.
Stoichitoiu
LE
,
Pinte
L
,
Balea
MI
,
Nedelcu
V
,
Badea
C
,
Baicus
C
.
Anticoagulant protein S in COVID-19: low activity, and associated with outcome
.
Rom J Intern Med
.
2020 Dec 17
;
58
(
4
):
251
8
.
41.
Baicus
C
,
Stoichitoiu
LE
,
Pinte
L
,
Badea
C
.
Anticoagulant protein S in COVID-19: the low activity level is probably secondary
.
Am J Ther
.
2021 Jan–Feb 1
;
28
(
1
):
e139
40
. .
42.
Chatterjee
S
,
Sengupta
T
,
Majumder
S
,
Majumder
R
.
COVID-19: a probable role of the anticoagulant protein S in managing COVID-19-associated coagulopathy
.
Aging
.
2020 Aug 31
;
12
(
16
):
15954
61
. .
43.
Cuker
A
,
Tseng
EK
,
Nieuwlaat
R
,
Angchaisuksiri
P
,
Blair
C
,
Dane
K
,
American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19
.
Blood Adv
.
2021 Feb 9
;
5
(
3
):
872
88
.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.